German criteria for reimbursement for EP testing in specialized centers (ASV criteria) for primary ER pos, HER2 neg BC in adjuvant settings recommend molecular gene expression assays for grade 2 (G2) tumors but not Ki67 > 30%, or for tumors with a Ki67 between 10 and 30% but not grade 3 (G3) for node negative (N0) patients and grade 1 (G1) or G2 tumors or tumors with Ki67 between 10 and 30% but not G3 or Ki67 > 30% in node-positive (1–3 positive lymph nodes) patients. This evidence concerns the gene ERBB2 and breast cancer.